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Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a congenital cardiac disease with myocardial 
involvement, most probably right ventricular (RV) dysfunction, accounting for 20% of sudden cardiac deaths. Characterized by 
the fibro-fatty infiltration of the RV free wall, ARVD/C presents in adolescents with ventricular arrhythmias and heart failure 
symptoms and as biventricular failure in adults. The coronary risk in these patients is not clear.
We present an incidental finding: the left anterior descending artery cut-off in a middle-aged man with ARVD/C. He had been 
under treatment for heart failure symptoms, which had decompensated frequently commencing 6 months earlier, and therefore 
he was scheduled for stem cell injection. He had no chest pain or coronary artery disease risk factors. Two-dimensional 
transthoracic echocardiography demonstrated RV enlargement with moderate to severe dysfunction and left ventricular 
ejection fraction (LVEF) of 35-40%, which was 45-50% two years before. Selective coronary angiography performed 8 years 
previously was normal but a new one revealed the cut-off of the left anterior descending artery at the proximal portion, for which 
percutaneous coronary intervention was performed and showed no significant lesion in the other vessels.
One should consider coronary artery disease in uncontrolled heart failure with LVEF reduction, even in the absence of typical 
chest pain. It may not be the natural course of the underlying disease.
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Introduction
Arrhythmogenic right ventricular dysplasia/
cardiomyopathy (ARVD/C) is a type of genetic 
cardiomyopathy first described in 1977 by Fontaine. It 
is characterized by the fibro-fatty infiltration of the right 
ventricle, which accounts for 20% of sudden cardiac deaths.1 
Due to certain abnormalities in heart-muscle proteins, 
they cannot keep the heart muscles together in stress-
like exercises. The cells become detached and die and are 
replaced with fibrous fatty tissue. As a result of these changes 
to the structure of the heart muscle, the walls of the ventricle 
become thin and stretched, which means that the heart cannot 
pump effectively.1, 2 Also, because of the changes to the heart 
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muscle cells, the normal passage of electrical impulses 
through the heart is interrupted or altered, which can cause 
life-threatening arrhythmias (abnormal heart rhythms) and 
sudden cardiac death. It manifests in teenage years with 
arrhythmias, dyspnea, and edema.
There are different options to establish a definite 
diagnosis but recently, echocardiography and especially 
cardiovascular magnetic resonance have been the most 
helpful. Patients should receive an implantable cardioverter-
defibrillator (ICD) and antiarrhythmic drugs and, in addition, 
conventional heart failure treatment should be considered.3, 4
Case Report
A 49-year-old Asian male was referred to the heart failure 
clinic due to exertional dyspnea, edema, and fatigue of 2 
years’ duration, which had exacerbated recently. He was a 
known case of ARVD/C. Eleven years before in 2001, he 
was admitted with sustained ventricular tachycardia; and 
after treatment with antiarrhythmic drugs, he was referred 
to Rajaei Cardiovascular, Medical and Research Center. The 
diagnosis was ARVD/C according to his echocardiography 
data: left ventricular ejection fraction of 55%, moderate right 
ventricular enlargement, mild right ventricular dysfunction, 
normal pulmonary artery pressure, mild mitral regurgitation, 
and moderate tricuspid regurgitation. Coronary angiography 
was normal and cardiovascular magnetic resonance was not 
available at the time. An ICD was inserted and antiarrhythmic 
drugs were tapered within 2 months.
He had been well since then with no events until he 
visited our clinic with complaints of dyspnea (New York 
Heart Association [NYHA] class II) and edema, which are 
signs of right ventricular failure. He had no chest pain, no 
coronary artery disease risk factors, and no history smoking. 
The jugular venous pressure was elevated in the upper neck, 
no specific sounds were heard in heart examination, and the 
lungs were clear. Electrocardiography revealed a normal sinus 
rhythm (heart rate of 45), poor R wave progression, no ST-T 
changes, and a narrow QRS (90 msec). Echocardiography 
was done once again and showed left ventricular 
ejection fraction of 40-45%, moderate right ventricular 
enlargement, moderate right ventricular dysfunction, no 
significant regional wall motion abnormalities, mild mitral 
regurgitation, moderate tricuspid regurgitation, and systolic 
pulmonary artery pressure of 35-40 mmHg. His laboratory 
data were as follows: normal  fasting blood sugar of 95 mg/
dl; pro-blood natriuretic peptide (proBNP) of 2357 pg/ml; 
total cholesterol of 195 mg/dl; low density cholesterol of 
125 mg/dl; high density cholesterol of 35 mg/dl; triglyceride 
of 157 mg/dl; normal cell blood count; urea of 45 mg/dl; 
creatinine of 1.2 mg/dl; sodium of 136 mg/dl; potassium of 
4.5 mg/dl; aspartate amino transferase of 35 mg/dl; alanine 
amino tranferase of 48 mg/dl; total bilirubin of 2.4 mg/dl; 
direct bilirubin of 0.9 mg/dl; uric acid of 8.9 mg/dl; thyroid 
stimulating hormone of 5.7 mg/dl ; and ferritin of 213 mg/dl.
In terms of the natural history of ARVD/C, the patient 
was in phase 3. Therefore, medication with Lisinopril, 
Carvedilol, Furosemide, Spironolactone, Folic Acid, and 
Sildenafil was commenced. Additionally, the ICD was 
programmed on a heart rate of 65. After 2 weeks, Lisinopril 
was discontinued because of hypotension, so Digoxin was 
started after reassurance of the heart rate.
He was in good physical condition (NYHA class I-II) 
on the above-mentioned treatment for 9 months, during 
which he was followed up every 2 months. Afterward, he 
referred to our clinic with edema and dyspnea. Furosemide 
was changed to Torasemide; his condition improved but 
he experienced symptoms relapse (NYHA class III) with 
no chest pain. Echocardiography and laboratory tests were 
repeated and the ICD was reprogrammed. There were no 
complications: proBNP increased to 2970, urea and liver 
enzymes rose mildly, and there was no anemia.
The patient had left ventricular ejection fraction of 35-
40%, mild hypokinesia in the septum, no change in the right 
ventricular size, and no pericardial effusion. Once more, 
based on the natural course of the disease, he was graded 
as phase 4. Accordingly, decision was made to evaluate him 
for heart transplantation. However, he was first candidated 
for stem cell injection in the hope of repairing the damaged 
myocardium. After he underwent bone marrow aspiration 
and mononuclear cell harvest in ROYAN Institute, he was 
transferred to our hospital, where angiography unexpectedly 
showed that the left anterior descending artery was cut off, 
while the other vessels were normal. Because it was not 
possible to perform cardiovascular magnetic resonance, 
the evaluation of the right ventricular function and left 
ventricular viability was done via stress echocardiography. 
The right ventricular data were similar to those mentioned 
before, and there was significant viability in the left anterior 
descending artery territory, so angioplasty was done on the 
left anterior descending artery.
On the last follow-up, the patient was in good condition 
(NYHA class I) and his jugular venous pressure and edema 
had improved. He is still on heart failure treatment, and the 
progression of right ventricular failure symptoms is not quite 
predictable.
Discussion
ARVD/C is an uncommon condition in which the 
myocardium is the site mainly involved. This condition 
has four phases: 1) a concealed phase in which the patient 
is asymptomatic; 2) overt electrical instability; 3) signs 
and symptoms of right ventricular failure; and 4) frank 
biventricular failure, which occurs in a minority of patients 
protected from sudden cardiac death.2, 5 Coronary disease is 
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rarely reported.6 Many cardiomyopathy patients reach the 
coronary artery disease age with some coronary risk factors, 
yet the possibility of atherosclerosis development cannot 
be predicted. The main chief complaint in heart failure is 
dyspnea; some patients have chest pain which can be due 
to pericardial involvement or low cardiac output, whereas 
others have no chest pain.
According to the guidelines, coronary angiography is 
indicated when there is typical chest pain or more than two 
coronary risk factors.7 However, is it preferable to consider 
coronary angiography when the patient has decompensated 
heart failure or has been admitted repeatedly in spite of full 
medical treatment. Moreover, it is advisable to take into 
account coronary disease when there is a reduction in the left 
ventricular ejection fraction, although biventricular failure is 
in the natural course of the disease.
Conclusion
Arrhythmogenic right ventricular dysplasia/
cardiomyopathy, which is now known as 
arrhythmogenic cardiomyopathy, is a progressively 
debilitating disease. As the patients are likely to reach 
the coronary disease age, it is prudent that coronary risk 
factors and coronary artery disease be considered in these 
patients. Future studies are required to determine whether 
revascularization can be beneficial or whether efforts should 
be solely focused on heart failure.
References
1. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke 
DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, 
Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz 
JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, 
Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic 
right ventricular cardiomyopathy/dysplasia: proposed modification 
of the task force criteria. Circulation 2010;121:1533-1541.  
2. Marron B, Olivotto L. Hypertrophic cardiomyopathy. In: Bonow 
RO,  Mann DL,  Zipes DP, Libby P, eds. Braunwald’s Heart 
Disease: A Text Book of Cardiovascular Medicine. 10th ed. 
Boston/Massachusetts: Elsevier Saunders; 2015: p.1574-1588.
3. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, 
Diwan A, Eschenbacher WH, Dorn LE, Watson MA, Margulies 
KB, Dorn GW, 2nd. Reciprocal regulation of myocardial 
microRNAs and messenger RNA in human cardiomyopathy and 
reversal of the microRNA signature by biomechanical support. 
Circulation 2009;119:1263-1271.
4. Dalal D, Molin LH, Piccini J, Tichnell C, James C, Bomma C, 
Prakasa K, Towbin JA, Marcus FI, Spevak PJ, Bluemke DA, 
Abraham T, Russell SD, Calkins H, Judge DP. Clinical features 
of arrhythmogenic right ventricular dysplasia/cardiomyopathy 
associated with mutations in plakophilin-2. Circulation 
2006;113:1641-1649.
5. Dalal D, Nasir K, Bomma C, Prakasa K, Tandri H, Piccini J, 
Roguin A, Tichnell C, James C, Russell SD, Judge DP, Abraham 
T, Spevak PJ, Bluemke DA, Calkins H. Arrhythmogenic right 
ventricular dysplasia: a United States experience. Circulation 
2005;112:3823-3832.
6. Asimaki A, Tandri H, Huang H, Halushka MK, Gautam S, Basso 
C, Thiene G, Tsatsopoulou A, Protonotarios N, McKenna WJ, 
Calkins H, Saffitz JE. A new diagnostic test for arrhythmogenic 
right ventricular cardiomyopathy. N Engl J Med 2009;360:1075-
1084.
7. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, 
Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates 
JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW; American 
College of Cardiology Foundation; American Heart Association. 
2009 focused update incorporated into the ACC/AHA 2005 
guidelines for the diagnosis and management of heart failure in 
adults: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines 
developed in collaboration with the International Society for Heart 
and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
Farveh Vakilian et al. 
